{"id":44535,"date":"2017-03-31T14:01:13","date_gmt":"2017-03-31T18:31:13","guid":{"rendered":"http:\/\/piel-l.org\/blog\/?p=44535"},"modified":"2017-04-01T17:32:04","modified_gmt":"2017-04-01T22:02:04","slug":"la-fda-aprueba-un-nuevo-medicamento-para-el-eccema","status":"publish","type":"post","link":"https:\/\/piel-l.org\/blog\/44535","title":{"rendered":"La FDA aprueba un nuevo medicamento para el eccema"},"content":{"rendered":"<p>Comunicado de Prensa de la FDA<br \/>\nMarch 28, 2017<\/p>\n<p>La Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en ingl\u00e9s) aprob\u00f3 hoy el Dupixent (dupilumab) en forma de inyecci\u00f3n para el tratamiento de adultos que padecen eccema (dermatitis at\u00f3pica) de moderada a severa. El Dupixent est\u00e1 indicado para los pacientes cuyo eccema no es adecuadamente controlado mediante los tratamientos t\u00f3picos, o aquellos para quienes estos tratamientos no son recomendables. El Dupixent puede utilizarse con o sin corticoides t\u00f3picos<\/p>\n<div class=\"su-button-center\"><a href=\"https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/ComunicadosdePrensa\/ucm549109.htm\" class=\"su-button su-button-style-flat\" style=\"color:#FFFFFF;background-color:#000954;border-color:#000844;border-radius:12px\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"color:#FFFFFF;padding:9px 30px;font-size:22px;line-height:33px;border-color:#4d5388;border-radius:12px;text-shadow:none\"><i class=\"sui sui-film\" style=\"font-size:22px;color:#FFFFFF\"><\/i> LEER ARTICULO COMPLETO<\/span><\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>La FDA aprob\u00f3 el Dupixent (dupilumab) en forma de inyecci\u00f3n para el tratamiento de adultos que padecen eccema (dermatitis at\u00f3pica) de moderada a severa<\/p>\n","protected":false},"author":4,"featured_media":44536,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"class_list":["post-44535","post","type-post","status-publish","format-standard","has-post-thumbnail","","category-farmacologia"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/44535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=44535"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/44535\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media\/44536"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=44535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=44535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=44535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}